LABORATORIO REIG JOFRE (RJF) AI Stock Analysis

• Market Cap: €245.83M
• Dividend Yield: 1.62%
• Average Volume (3M): 40.25K
• Price to Earnings (P/E): 37.1
• Beta (1Y): 0.34
• Revenue Growth: 0.58%
• EPS Growth: -30.60%
• Country: ES
• Employees: 1,331
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 82,219,240
• 10 Day Avg. Volume: 53,830
• 30 Day Avg. Volume: 40,247
• PEG Ratio: 2.30
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 0.59
• P/FCF Ratio: 18.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.50
• Price Target Upside: 17.06% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: €3.50 ▲(17.06% Upside)

The overall stock score is driven primarily by strong financial performance, with consistent revenue and profit growth, and solid cash flow. Technical analysis shows positive price trends, though caution is advised due to potential overvaluation as indicated by the high P/E ratio.

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.

How the Company Makes Money

Laboratorio Reig Jofre generates revenue through the sale of its pharmaceutical products, which include both prescription medications and over-the-counter drugs. The company operates on a business model that encompasses direct sales to hospitals, pharmacies, and healthcare providers, as well as partnerships with other pharmaceutical companies for the distribution of its products. Additionally, RJF may engage in licensing agreements and collaborations for research and development, contributing to its revenue streams. The company's focus on innovative therapies and expanding its product portfolio in response to market demand also plays a significant role in driving sales and earnings.

LABORATORIO REIG JOFRE Financial Statement Overview

Summary

LABORATORIO REIG JOFRE shows robust financial performance with strong revenue growth, improved profit margins, and healthy cash flow generation. The balance sheet is solid with manageable debt levels and good equity ratio, indicating financial stability and growth potential.

Income Statement

The company has demonstrated a strong revenue growth trajectory, with a notable increase from €316.09M to €338.90M year-over-year, marking a 7.22% growth rate. Gross Profit Margin is healthy at 57.73%, indicating efficient cost management. The Net Profit Margin improved to 3.06%, reflecting better profitability. EBIT and EBITDA margins are stable at 3.72% and 10.68% respectively, though room for improvement remains.

Balance Sheet

The Debt-to-Equity ratio is reasonable at 0.27, indicating a balanced leverage. Return on Equity is moderate at 4.85%, suggesting efficient asset utilization. The company maintains a good Equity Ratio of 62.06%, supporting financial stability. Overall, the balance sheet reflects sound financial health with manageable debt levels.

Cash Flow

Operating Cash Flow has increased significantly to €31.34M, showcasing strong cash-generating ability. Free Cash Flow to Net Income ratio is 1.02, indicating effective cash management. Free Cash Flow grew by 66.37%, reflecting improved financial flexibility. The company is well-positioned to meet its short-term obligations and invest in growth opportunities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	415.66M	338.89M	316.09M	271.15M	236.23M	230.08M
Gross Profit	244.01M	195.68M	176.89M	69.58M	144.98M	140.40M
EBITDA	38.46M	36.18M	33.89M	30.44M	24.66M	24.31M
Net Income	8.86M	10.38M	9.41M	8.11M	5.09M	5.67M
Balance Sheet
Total Assets	357.56M	344.85M	330.55M	321.19M	324.98M	317.15M
Cash, Cash Equivalents and Short-Term Investments	10.84M	16.08M	6.36M	6.88M	5.16M	11.69M
Total Debt	67.06M	58.52M	53.49M	61.24M	67.38M	57.02M
Total Liabilities	141.17M	130.90M	126.29M	126.64M	136.46M	132.67M
Stockholders Equity	216.42M	213.97M	204.35M	194.63M	188.59M	184.55M
Cash Flow
Free Cash Flow	0.00	10.56M	6.34M	4.75M	-5.26M	6.55M
Operating Cash Flow	0.00	31.34M	19.11M	16.15M	14.50M	22.50M
Investing Cash Flow	0.00	-31.96M	-12.88M	-12.72M	-34.70M	-30.70M
Financing Cash Flow	0.00	5.59M	-7.16M	-2.04M	13.67M	9.62M

LABORATORIO REIG JOFRE Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Positive. The current price of 2.99 is below the 20-day moving average (MA) of 2.99, above the 50-day MA of 2.92, and above the 200-day MA of 2.85, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.42 is Neutral, neither overbought nor oversold. The STOCH value of 2.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:RJF.

LABORATORIO REIG JOFRE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	77 Outperform	€1.40B	13.30	14.89%	3.97%	11.04%	8.29%
ROVI	71 Outperform	€3.05B	23.19	25.44%	1.56%	-3.73%	-7.56%
RJF	68 Neutral	€245.83M	37.07	3.04%	1.62%	0.58%	-30.60%
ALM	53 Neutral	€2.60B	121.20	1.45%	1.30%	13.32%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATRY	51 Neutral	€245.41M	―	-9.43%	―	15.90%	37.03%
ORY	48 Neutral	€272.04M	―	-4.53%	―	―	-2.02%